KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Retained Earnings (2018 - 2025)

Aurinia Pharmaceuticals' Retained Earnings history spans 7 years, with the latest figure at -$599000.0 for Q4 2025.

  • For Q4 2025, Retained Earnings rose 7.42% year-over-year to -$599000.0; the TTM value through Dec 2025 reached -$599000.0, up 7.42%, while the annual FY2025 figure was -$599000.0, 7.42% up from the prior year.
  • Retained Earnings reached -$599000.0 in Q4 2025 per AUPH's latest filing, up from -$749000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$599000.0 in Q4 2025 to a low of -$952.3 million in Q2 2024.
  • Average Retained Earnings over 5 years is -$414.1 million, with a median of -$313.7 million recorded in 2021.
  • Peak YoY movement for Retained Earnings: tumbled 105473.8% in 2022, then surged 99.93% in 2024.
  • A 5-year view of Retained Earnings shows it stood at -$756.1 million in 2021, then decreased by 14.31% to -$864.3 million in 2022, then fell by 9.03% to -$942.3 million in 2023, then soared by 99.93% to -$647000.0 in 2024, then rose by 7.42% to -$599000.0 in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Retained Earnings are -$599000.0 (Q4 2025), -$749000.0 (Q3 2025), and -$905000.0 (Q2 2025).